ADHD pills lead to other drugs, hormone therapy guidelines have been updated and Novo Nordisk and Eli Lilly cut obesity drug prices. Read more in this week’s WSJ Health newsletter:

• ADHD medications are linked to the use of additional drugs, highlighting potential concerns in treatment approaches. New hormone therapy guidelines have also been introduced, reflecting evolving medical standards.
• The price reductions for obesity drugs by Novo Nordisk and Eli Lilly may increase accessibility for patients, potentially impacting market dynamics and competition in the obesity treatment sector.

— via World Pulse Now AI Editorial System